Girish Kunapareddy, MD

Experts discuss the future outlook for chimeric antigen receptor T-cell therapy (CAR T) in diffuse large B-cell therapy (DLBCL), exploring potential advancements and evolving treatment strategies.

Experts discuss the advantages and limitations of outpatient administration for chimeric antigen receptor T-cell therapy (CAR T) and how potential issues with outpatient administration can be addressed.

Experts discuss strategies for monitoring and managing cytokine release syndrome (CRS) and neurotoxicity, the influence of key takeaways from cohorts 4 and 6 of the ZUMA-1 trial on their practice, and how post- chimeric antigen receptor T-cell therapy (CAR T) follow-up care is managed between academic and community settings.

Experts discuss when a patient should be referred from community practice to an academic or specialized program, the factors influencing the choice and timing of bridging therapy before CAR T infusion, and how bridging therapy is coordinated between academic and community settings.

Experts discuss the main operational challenges faced in the community setting when it comes to chimeric antigen receptor T-cell therapy (CAR T) and the best practices implemented to mitigate these challenges.

Experts discuss what they share with patients when counseling about the benefits and risks of chimeric antigen receptor T-cell therapy (CAR T).

Experts discuss the patient factors and disease characteristics that influence the selection of chimeric antigen receptor T-cell therapy (CAR T) options, how to determine if a patient is an appropriate candidate, and when to begin considering CAR T in the treatment journey.

Experts discuss how they sequence bispecifics and other available therapies in the third-line setting and beyond for patients who did not receive chimeric antigen receptor T-cell therapy (CAR T) in the second-line setting, and whether their approach changes for those who have or have not received prior auto-transplant.

Experts discuss the role of chimeric antigen receptor T-cell therapy (CAR T) in the treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), how they sequence between bispecific antibodies and CAR T, the frequency and patient selection for CAR T in the second-line setting, and key takeaways from a recent oral presentation on real-world outcomes with axicabtagene ciloleucel (axi-cel) in the second-line setting from ASH 2024.